Pharmala Biotech : CEO Letter To Shareholders
From the desk of Nick Kadysh, Founding CEO, PharmAla Biotech Over the past 48 hours, a large number of shareholders have reached out to me for my thoughts on the recent FDA...
Stay updated with breaking news from Pharmala Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
From the desk of Nick Kadysh, Founding CEO, PharmAla Biotech Over the past 48 hours, a large number of shareholders have reached out to me for my thoughts on the recent FDA...
LaNeo Product Data submitted for a Clinical Trial in CanadaTORONTO, March 26, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA, OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it had entered into a binding sales agreement with Numinus Wellness Inc. (“Numinus”) (TSX: NUMI, OTCQX: NUMIF) to provide its GMP LaNeo
Red Light Holland Corp. , a company engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe and a premium bra...